DLL3 and large cell neuroendocrine carcinoma: Rova-T is an ADC comprised of a humanized anti-DLL3 mAb conjugated to a DNA-damaging pyrrolobenzodiazepine (PBD) dimer toxin that has been shown to induce sustained tumor regression across neural crest–derived malignancies including SCLC and LCNEC patient-derived xenograft (PDX) models (5).